Literature DB >> 21297883

Genome-Targeted Drug Design: Understanding the Netropsin-DNA Interaction.

Ya-Yin Fang1, Vernon R Morris, Guy M Lingani, Eric C Long, William M Southerland.   

Abstract

Knowledge of the sequence of the human genome has provided significant opportunities to exploit DNA as a target in the rational design of therapeutic agents. Among agents that target DNA, netropsin exhibits a strong preference for binding A/T rich regions. In order to investigate the key factors responsible for DNA recognition and binding by netropsin, molecular dynamics simulations were carried out on a DNA-netropsin complex in which two netropsin molecules are bound to each AATT site of the 16-mer d(CTTAATTCGAATTAAG)(2). In this complex, the two netropsins are bound to the DNA minor groove in a head-to-head orientation with the guanidinium-termini of both netropsins pointed toward the center of the DNA. Despite their identical environments, molecular dynamics simulations showed that the two netropsins exhibited differences in their respective RMS behaviors, binding energies, minor groove width fluctuations, and rotations of their structural planes. These observations suggest that DNA recognition and binding by small molecules may be governed by mechanism(s) that are much more complex than initially anticipated and may represent unexpected challenges in genome-targeted drug design.

Entities:  

Year:  2010        PMID: 21297883      PMCID: PMC3032215          DOI: 10.2174/22102892010010100157

Source DB:  PubMed          Journal:  Open Conf Proc J


  9 in total

Review 1.  DNA minor-groove recognition by small molecules.

Authors:  S Neidle
Journal:  Nat Prod Rep       Date:  2001-06       Impact factor: 13.423

2.  Significance of ligand tails for interaction with the minor groove of B-DNA.

Authors:  B Wellenzohn; W Flader; R H Winger; A Hallbrucker; E Mayer; K R Liedl
Journal:  Biophys J       Date:  2001-09       Impact factor: 4.033

Review 3.  Recognition of the DNA minor groove by pyrrole-imidazole polyamides.

Authors:  Peter B Dervan; Benjamin S Edelson
Journal:  Curr Opin Struct Biol       Date:  2003-06       Impact factor: 6.809

4.  X-ray structures of the B-DNA dodecamer d(CGCGTTAACGCG) with an inverted central tetranucleotide and its netropsin complex.

Authors:  K Balendiran; S T Rao; C Y Sekharudu; G Zon; M Sundaralingam
Journal:  Acta Crystallogr D Biol Crystallogr       Date:  1995-03-01

5.  Cloning, expression, and purification of a catalytic fragment of Moloney murine leukemia virus reverse transcriptase: crystallization of nucleic acid complexes.

Authors:  D Sun; S Jessen; C Liu; X Liu; S Najmudin; M M Georgiadis
Journal:  Protein Sci       Date:  1998-07       Impact factor: 6.725

Review 6.  DNA recognition by lexitropsins, minor groove binding agents.

Authors:  J W Lown
Journal:  J Mol Recognit       Date:  1994-06       Impact factor: 2.137

7.  Arresting cancer proliferation by small-molecule gene regulation.

Authors:  Liliane A Dickinson; Ryan Burnett; Christian Melander; Benjamin S Edelson; Paramjit S Arora; Peter B Dervan; Joel M Gottesfeld
Journal:  Chem Biol       Date:  2004-11

8.  Structural consequences of a carcinogenic alkylation lesion on DNA: effect of O6-ethylguanine on the molecular structure of the d(CGC[e6G]AATTCGCG)-netropsin complex.

Authors:  M Sriram; G A van der Marel; H L Roelen; J H van Boom; A H Wang
Journal:  Biochemistry       Date:  1992-12-01       Impact factor: 3.162

9.  A host-guest approach for determining drug-DNA interactions: an example using netropsin.

Authors:  Kristie D Goodwin; Eric C Long; Millie M Georgiadis
Journal:  Nucleic Acids Res       Date:  2005-07-27       Impact factor: 16.971

  9 in total
  1 in total

1.  Structural and energetic insights into sequence-specific interaction in DNA-drug recognition: development of affinity predictor and analysis of binding selectivity.

Authors:  Jingheng Ning; Weiwei Chen; Jiaojiao Li; Zaixi Peng; Jianhui Wang; Zhong Ni
Journal:  J Mol Model       Date:  2012-12-29       Impact factor: 1.810

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.